Crossmark

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

Published Online: 2024-02-23

Authors

Zhao, Dehua

Long, Xiaoqing

Wang, Jisheng
License Information

Text and Data Mining valid from 2024-02-23

Version of Record valid from 2024-02-23
More Information

Article History

Received: 30 June 2023

Accepted: 9 February 2024

First Online: 23 February 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current